Auriga files patent application to expand Extendryl line

By Lisa Kerner

Charlotte, N.C., Sept. 15 - Auriga Laboratories, Inc. filed a provisional patent application for proprietary technology to be used to expand its Extendryl line of seven prescription drug products in the multibillion-dollar prescription cough, cold and allergy treatment market.

The patent application covers formulations administering methscopolamine in multi-phasic drug release: immediate, sustained, delayed, pulsed and gradient.

"This particular patent application is exciting because it will yield market exclusivity of our popular prescription cold medicine Extendryl," chief executive officer Philip S. Pesin said in a news release.

Auriga is a specialty pharmaceutical company located in Norcross, Ga.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.